Creatine Kinase BB Isoenzyme (CK-BB)
Homodimeric isozyme composed of two B subunits (BB), localized in the brain, gastrointestinal tract, and smooth muscle.
Standard vs. Optimal Reference Ranges%
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<1.0% of total CK (undetectable in serum)
General reference distribution across unselected commercial populations.
Undetectable (<0.5%)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Normally excluded from systemic circulation by the blood-brain barrier; presence indicates severe cerebral necrosis or bowel infarction.
Differential Diagnosis
Elevated Levels (CK-BB High)
- •Severe acute cerebral infarction / stroke
- •Mesenteric arterial ischemia / bowel infarction
- •Oat cell carcinoma of the lung
Low Levels (CK-BB Low)
- •Intact blood-brain barrier and intestinal mucosa
- •Normal baseline
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for CK-BB
- Targeted organ system imaging or functional dynamic testing related to brain & smooth muscle isozyme
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Creatine Kinase BB Isoenzyme - The New England Journal of Medicine (2021). PMID: 34190124
- [2]CK-BB Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Creatine Kinase BB Isoenzyme (CK-BB) into overall healthspan optimization.